PMID- 36244642
OWN - NLM
STAT- MEDLINE
DCOM- 20221130
LR  - 20221130
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 180
DP  - 2022 Dec
TI  - Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An 
      overview of systematic reviews.
PG  - 103842
LID - S1040-8428(22)00266-9 [pii]
LID - 10.1016/j.critrevonc.2022.103842 [doi]
AB  - In this overview we present a summary of evidence from systematic reviews (SRs) 
      on the safety and efficacy of carfilzomib in multiple myeloma (MM). Our search in 
      electronic databases and conference proceedings yielded 14 eligible SRs, graded 
      as of low overall quality with the AMSTAR-2 tool. The Corrected Covered Area 
      index was 52.3% which shows very high overlap among studies. Carfilzomib was 
      shown to increase progression free survival (HR=0.61, 95%CI=0.47-0.78, p = 0.01, 
      I(2) =73%), overall survival (HR=0.79,95%CI=0.66-0.95, p = 0.01, I(2) =0) and 
      overall response rate (OR=2.4,95% CI=1.6-3.4, p < 0.001, I(2) =99%) in 
      relapsed/refractory MM (RRMM); all with moderate quality of evidence assessed 
      with the GRADE approach. Carfilzomib was associated with cardiovascular adverse 
      events (AEs) (RR=2.2, 95%CI=1.6-2.9, p < 0.001, I(2) =0), nephrotoxicity 
      (RR=1.79, 95% CI=1.43-2.23, p < 0.001, I(2) =39%) and serious infections 
      (RR=1.40, 95%CI=1.17-1.69, p < 0.001, I(2) =57%). Concluding, carfilzomib is 
      effective in RRMM, but associated with certain AEs. More randomized clinical 
      trials and high-quality SRs, especially on newly diagnosed patients are needed.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Georgoulis, Vasileios
AU  - Georgoulis V
AD  - Department of Haematology, University Hospital of Ioannina, Ioannina, Greece.
FAU - Haidich, Anna-Bettina
AU  - Haidich AB
AD  - Department of Hygiene, Social-Preventive Medicine & Medical Statistics, School of 
      Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 
      Thessaloniki, Greece.
FAU - Bougioukas, Konstantinos I
AU  - Bougioukas KI
AD  - Department of Hygiene, Social-Preventive Medicine & Medical Statistics, School of 
      Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 
      Thessaloniki, Greece.
FAU - Hatzimichael, Eleftheria
AU  - Hatzimichael E
AD  - Department of Haematology, Faculty of Medicine, School of Health Sciences, 
      University of Ioannina, Ioannina, Greece. Electronic address: ehatzim@uoi.gr.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221013
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 72X6E3J5AR (carfilzomib)
RN  - 0 (Oligopeptides)
SB  - IM
MH  - Humans
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Multiple Myeloma/drug therapy
MH  - *Oligopeptides/therapeutic use
MH  - Systematic Reviews as Topic
OTO - NOTNLM
OT  - Carfilzomib
OT  - Efficacy
OT  - Multiple myeloma
OT  - Overview
OT  - Proteasome inhibitor
OT  - Safety
COIS- Conflict of interest statement This research did not receive any specific grant 
      from funding agencies in the public, commercial, or not-for-profit sectors. V.G., 
      A.B.H. and K.I.B declare no conflict of interest. E.H. declares the following: 
      Honoraria/Advisory Board/Consultancy: Astra Zeneca, Abbvie, Roche, Amgen, Gilead, 
      Glaxo-Smithkline, Janssen Cilag, Genesis, Abbvie, Takeda, Pharmathen- Innovis, 
      Teva, Sanofi, BMS, Celgene, Pfizer.
EDAT- 2022/10/17 06:00
MHDA- 2022/11/30 06:00
CRDT- 2022/10/16 19:47
PHST- 2022/09/03 00:00 [received]
PHST- 2022/10/04 00:00 [revised]
PHST- 2022/10/11 00:00 [accepted]
PHST- 2022/10/17 06:00 [pubmed]
PHST- 2022/11/30 06:00 [medline]
PHST- 2022/10/16 19:47 [entrez]
AID - S1040-8428(22)00266-9 [pii]
AID - 10.1016/j.critrevonc.2022.103842 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2022 Dec;180:103842. doi: 
      10.1016/j.critrevonc.2022.103842. Epub 2022 Oct 13.